INDOGULF CROPSCIENCES LTD – Q1 FY27 CONCALL HIGHLIGHTS
#Q1FY27
Q1FY27 Financial Performance
- Consolidated revenue stood at
₹168.5 Cr, down
11% YoY.
- Revenue increased
12% QoQ from ₹150.8 Cr.
- Gross profit increased
12% YoY to
₹46.6 Cr.
- Gross margin improved to
28% from 22%.
- EBITDA stood at
₹9.6 Cr, down around 4% YoY.
- EBITDA margin improved to
5.7% from 5.2%.
- PAT stood at
₹2.4 Cr vs ₹3.9 Cr YoY.
- PAT margin stood at
1.4% vs 2.1%.
- Capacity utilization improved to
70% from 52% in FY26.
- Margin resilience supported by better product mix.
- Procurement discipline also supported profitability.
Industry & Monsoon Environment
- Q1 faced delayed and uneven southwest monsoon.
- Delayed sowing impacted crop protection demand.
- Some regions witnessed crop resowing.
- Herbicide demand was particularly affected.
- Crop patterns shifted across key crops.
- Farmer spending remained cautious.
- Dealers remained cautious on inventory stocking.
- Fertilizer stocking absorbed channel liquidity.
- Lower commodity realizations affected farmer economics.
- Global supply remained elevated, especially from China.
- Pricing remained under pressure during Q1.
- Management views weakness as largely
time-related.
- Kharif and Rabi demand expected to remain sustainable.
- Management does not expect exceptionally high growth FY27.
Business Mix & Distribution
- Crop protection contributed
87% of Q1 revenue.
- Biologicals contributed around
3%.
- Plant nutrients contributed around
3%.
- B2C contributed
47% of revenue.
- B2B contributed
40% of revenue.
- Exports contributed
13% of revenue.
- More than
100 development officers across India.
- Farmer engagement crossed
1 lakh farmers.
- Field trials and advisory programs support adoption.
- Channel partner engagement continues to deepen.
Backward Integration
- Captive technical consumption increased to
34%.
- Earlier captive consumption was around
22%.
- Backward integration improves cost competitiveness.
- It also improves technical availability.
- Timely supply supports formulation opportunities.
- Company plans to expand backward integration.
- Product portfolio will increasingly utilize captive technicals.
- Some molecules remain dependent on China.
- Biologicals and nutrients are largely captive sourced.
- Backward manufacturing provides a competitive edge.
Biologicals & Plant Nutrition
- Segment is a major emerging opportunity.
- Product basket is being expanded aggressively.
- Focus includes stress-tolerance products.
- Plant-signaling products are under development.
- Physics and biology-based technologies are being explored.
- ICAR-IARI collaboration is underway for
3 years.
- Focus includes heat and drought resistance.
- New formulation types are being developed.
- USP creation through formulation and packaging continues.
- Certification and process technology remain priorities.
- Biologicals and plant nutrition sales mix improved.
- Mix increased from
11% to 22% YoY.
- Higher-margin products should improve profitability.
International Expansion
- Global registrations reached
189.
- More than
120 registrations are valid.
- Over
10 registrations are under renewal.
- Mancozeb 80% WP registered in Taiwan.
- Spiromesifen technical shipment completed in Taiwan.
- Additional Taiwan formulation registration underway.
- Vietnam formulation registration is progressing.
- Indo Apache received Sri Lanka import permission.
- Five technical registrations secured in Saudi Arabia.
- Expansion continues across Kenya, Nigeria and Tanzania.
- Venezuela remains an important market.
- Brazil is being strategically evaluated.
- LATAM, Africa and Middle East remain priorities.
- China export incentive changes create opportunity.
- Benefits expected more meaningfully over longer term.
Australia Subsidiary
- Australia entity primarily supports registrations.
- It supports OECD registration requirements.
- Australia is not currently a marketing focus.
- Near-term focus remains India and other regions.
- LATAM, Africa and Middle East offer opportunities.
- Australia marketing may not start for
1–2 years.
Innovation & New Products
- Two of three FY27 specialty products launched.
- New fungicide remains on track for Q2 launch.
- Launch subject to relevant patent expiry.
- Specialty products remain strategic growth focus.
- Higher-value products should improve portfolio quality.
- ICAR-IARI collaboration supports next-generation solutions.
- Heat and drought products remain under development.
Manufacturing & Capacity
- Existing capacity can support
₹1,100–1,200 Cr turnover.
- Extended capacity can support around
₹1,800 Cr+.
- New capacity should support next several years.
- Management expects ₹1,800 Cr over
4–5 years.
- Barwasni expansion is progressing.
- DF manufacturing facility is under development.
- Capital work-in-progress stood at
₹76.4 Cr.
- FY25 capital work-in-progress was ₹57.1 Cr.
- Manufacturing efficiency remains a key focus.
Margins & Return Ratios
- Product mix is the key ROCE lever.
- Biologicals and nutrients offer higher margins.
- Manufacturing yield improvement remains important.
- Energy efficiency initiatives continue.
- Procurement and supply-chain optimization remain priorities.
- Higher asset utilization should improve returns.
- Working-capital efficiency remains a key focus.
- Goal is earnings growth faster than capital employed.
- Management expects gradual margin improvement.
Working Capital & Finance Cost
- Finance cost increased
19% YoY.
- Inventory was built anticipating stronger sales.
- Delayed demand resulted in inventory buildup.
- Management expects inventory liquidation ahead.
- Better collections should reduce finance costs.
- Cost discipline remains a key priority.
M&A & Growth Strategy
- Company is evaluating inorganic opportunities.
- Focus remains on domestic organic expansion.
- Existing brands have significant India opportunity.
- M&A discussions cover global opportunities.
- Technology acquisition is one focus area.
- Market expansion is another focus area.
- No concrete transaction has been finalized.
- Integrated agri-solutions platform remains long-term vision.
- Focus spans crop protection, nutrients and biologicals.
- Geographic integration remains an important advantage.
FY27 Outlook
- Management did not provide specific growth guidance.
- Company aims to deliver strong growth.
- Q1 industry weakness was largely seasonal.
- Kharif performance is being closely monitored.
- Rabi sustainability remains an important focus.
- Management expects continued business growth.
- Cost and operational actions aim to protect margins.
KEY TAKEAWAY
-
Weak monsoon hurt Q1; mix and integration support recovery.
Daily Live Quarterly Result Updates
@Stockupdate9